Bristol-Myers Squibb (NYSE:BMY) Position Reduced by ORG Partners LLC

ORG Partners LLC decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 67.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,294 shares of the biopharmaceutical company’s stock after selling 2,688 shares during the period. ORG Partners LLC’s holdings in Bristol-Myers Squibb were worth $69,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Northwest Financial Advisors acquired a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $27,000. Accordant Advisory Group Inc acquired a new position in Bristol-Myers Squibb in the first quarter worth approximately $31,000. Pacific Capital Wealth Advisors Inc. acquired a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $34,000. VisionPoint Advisory Group LLC grew its position in Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 553 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $40,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.8 %

NYSE BMY traded down $0.32 on Friday, hitting $40.43. The company’s stock had a trading volume of 12,818,822 shares, compared to its average volume of 15,662,419. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $65.38. The company’s 50-day moving average is $41.99 and its 200 day moving average is $47.47. The firm has a market cap of $81.96 billion, a PE ratio of -13.15, a PEG ratio of 14.07 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the prior year, the company posted $2.05 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.94%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Barclays lowered their price objective on shares of Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating on the stock in a research report on Wednesday. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $59.50.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.